Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...
Blue Sail Medical’s Fastroad Catheter Earns NMPA Marketing Approval
Blue Sail Medical Co., Ltd (SHE: 002382), a medical device company based in China, has...
Philips Appoints Liu Ling as Greater China President Amid Leadership Changes
Dutch multinational Philips has appointed Liu Ling as President of Greater China, effective immediately. Liu...
CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...
Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America
Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL...
GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership
GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership...
China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions
Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its...
LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China
LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...
AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...
Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round
Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
Novartis Launches Construction of First Radioligand Manufacturing Site in China
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...
China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru
MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...
Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study
Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...
Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval
Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...